London · Delayed Price · Currency is GBP · Price in USD Centessa Pharmaceuticals Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2.
The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders.
In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 77 |
| CEO | Saurabh Saha |
Contact Details
Address: 1 Ashley Road Altrincham, WA14 2DT United Kingdom | |
| Phone | 44 617 4685770 |
| Website | centessa.com |
Stock Details
| Ticker Symbol | 0ACX |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Saurabh Saha | Chief Executive Officer |
| John Crowley | Chief Financial Officer |
| Kristen Sheppard | Head of Investor Relations |